Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) will end internally funded development of SkinJect for sporadic nodular basal cell carcinoma and concentrate its clinical spending on Gorlin syndrome, narrowing …
ICYMI: Medicus Narrows SkinJect Program to Gorlin Syndrome Read More
PHILADELPHIA, PA — FMC Corporation (NYSE: FMC) is advancing two RNA-based bioinsecticide candidates into field trials across the United States, Brazil and Asia, moving its collaboration with AgroSpheres from controlled …
FMC Advances RNA Bioinsecticides Into Global Field Trials Read More
WILMINGTON, DE — Trialbee has added an artificial intelligence pre-screening agent to its Honey Platform to identify ineligible clinical trial candidates earlier and move qualified referrals to research sites faster, …
Trialbee Adds AI Screening to Cut Clinical Trial Referral Delays Read More
PHILADELPHIA, PA — Imvax Inc. is preparing a roughly 375-patient Phase 3 trial of its experimental glioblastoma therapy IGV-001 after a prespecified Phase 2b subgroup analysis showed longer median survival …
Imvax Glioblastoma Data Backs Move Toward Phase 3 Trial Read More
YARDLEY, PA — Jubilant Therapeutics reported early clinical activity for JBI-802 in a Phase 1/2 trial of patients with myeloproliferative neoplasms, with dose-responsive platelet reductions observed across several disease subtypes …
Jubilant Reports Early Platelet Reductions With JBI-802 Read More PHILADELPHIA, PA — Medicus Pharma is ending further development of SkinJect for sporadic nodular basal cell carcinoma and concentrating its investment on an FDA-authorized Phase 2b study in Gorlin syndrome, …
Medicus Narrows SkinJect Program to Gorlin Syndrome Read More
WILMINGTON, DE — AstraZeneca (NYSE: AZN) and Daiichi Sankyo’s Enhertu extended median progression-free survival by six months versus pembrolizumab plus chemotherapy in a Phase III trial of first-line treatment for …
Enhertu Extends PFS by Six Months in HER2 Lung Cancer Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) Tagrisso showed a sustained survival benefit eight years after treatment in a Phase III trial of patients with early-stage EGFR-mutated non-small cell lung cancer, …
Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration finalized an expedited regulatory pilot that will pair drug companies with qualified research institutions to shorten the path to first-in-human clinical …
FDA Opens Expedited Drug Trial Pilot to Cut Development Delays Read More WILMINGTON, DE — AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of first-line extensive-stage small cell lung cancer, potentially expanding treatment options for …
AstraZeneca Lung Cancer Combo Extends Survival in Phase III Read More